PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as

Note: A certificate of mailing an of the feet of any other accompanying papers, Each additional papers	indicated unless corrected I maintenance fee notification	below or directed otherwise	in Block 1, by (a) specifying	a new correspondence address	s; and/or (b) indicating a sepa	arate "FEE ADDRESS" for
MORGAN LEWIS & BOCKIUS LLP ITH PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004 WASHINGTON, DC 20004 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 99889,599 10/19/2001 Jason G Kertle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLINATIVE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 1. Change of correspondence address or indication of "Fee Address" (17 CFR 1.363). Change of correspondence address (or Change of Correspondence Address from PTO/SB/1/2) attached. The relation of the patent front type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of a substitute for filing an assignment has been previously submitted to the USPTO or tategories (will not be printed on the patent); Old Patence Address and Signee Category or categories (will not be printed on the patent); Old Patence Address and Signee category or categories (will not be printed on the patent); Old Patence Address and Signee category or categories (will not be printed on the patent); Old Patence Address and Patence Address (or Companies on the patent); Old Patence Address and Provided Address (or Companies on the patent); Old Patence Address (or Companies and Signee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. ART UNIT CLASS-SUBCLAS 1. Change of Correspondence address (or Change of Correspondence address (or Change of Correspondence address); or Change of Correspondence address (or Change of Correspondence address); or Change of Correspondence address (or Change of Correspondence address (or Change of Correspondence address); or Change of Correspondence address (or Change of Correspondence address); or Change of Corresponde			with any corrections or use Block 1)	Note: A certificate o Fee(s) Transmittal. T papers. Each addition	f mailing can only be used for his certificate cannot be used and paper, such as an assignment	or domestic mailings of the for any other accompanying ent or formal drawing, must
I hereby certify that this Fee(s) Transmittal is being deposited with the United WASHINGTON, DC 20004 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. O99889,599 10719/2001 Jason G Kettle P 20281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(s) DUE DATE DUE nonprovisional NO \$1330 \$50 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 \$14-415000 1. Change of correspondence address or indication of "Fee Address" (37 CRIS.53). Change of correspondence address for Change of Correspondence address of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is a bashitute for filing an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is a bashitute for filing an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is a bashitute for filing an assignment last been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is abshitute for filing an assignment has been previously submitted under separate cover. Completion of this form is abshitute for filing an assignment last been previously submitted to the USPTO or is being submitted under separate cover. Completion of thi			IPE	have its own certifica	te of mailing or transmission.	_
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/889,599 10/19/2001 Jason G Kettle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.543). CR1.363). Change of correspondence address or indication of "Fee Address" (37 CFR 1.561). Change of correspondence address (or Change of Correspondence Address (or Change of Correspondence Address (indication for "Fee Address" indication for "Fee Address indication for "Fee Address indication for "Fee Address" indication for "Fee Address in	1111 PENNSYLV	ania avenue nw/		I hereby certify that to States Postal Service addressed to the Matransmitted to the US	ertificate of Mailing or Trans this Fee(s) Transmittal is bein with sufficient postage for fin all Stop ISSUE FEE address PTO, on the date indicated bel	smission g deposited with the United st class mail in an envelope above, or being facsimile low.
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/889,599 10/19/2001 Jason G Kettle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.543). CR1.536). Change of correspondence address or indication of "Fee Address" (37 CFR 1.545). The Address from PTO/SB/122 attached. Or "Tee Address" indication for "Fee Address indication for indication for indication for indication for indi		_	o Main			(Depositor's name)
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/889,599 10/19/2001 Jason G Kettle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CR 1.563). Change of correspondence address (or Change of Correspondence Address from PTO/SB47, Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden		•				(Signature)
O9/889,599 10/19/2001 Jason G Kettle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.369). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. Pleas Address from PTO/SB/122) attached. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent, Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); individual XX corporation or other private group entity Q government data. The following fee(s) are enclosed: 4b. Payment of Fee(s):			A MADE			(Date)
O9/889,599 10/19/2001 Jason G Kettle P 0281500 6903 TITLE OF INVENTION: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563). Change of correspondence address (or Change of Correspondence Address from PTO/SB/122) attached. O "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached. O "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached. SASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AS traZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); Individual XX corporation or other private group entity Individual Assignment of Fee(s):	APPLICATION NO.	FILING DATE	FIRST NAME	D INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563). □ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. □ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden	09/889,599	10/19/2001	Jason (G Kettle	P 0281500	
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. CFR eddress" indication (or "Fee Address" Indication form PTO/SB/122) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); Individual XX corporation or other private group entity Individual Capture of the private group entity Individual Capture or the private group entity In	•		•		1 0201300	
nonprovisional NO \$1330 \$0 \$1330 03/19/2004 EXAMINER ART UNIT CLASS-SUBCLASS ROBINSON, BINTA M 1625 514-415000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). □ Change of correspondence address (or Change of Correspondence Address form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filling an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden						
ROBINSON, BINTA M 1625 1. Change of correspondence address or indication of "Fee Address" (37 1. Change of correspondence address or indication of "Fee Address" (37 1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. 1. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached. 1. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached. 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); individual Xxcorporation or other private group entity individual	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
ROBINSON, BINTA M 1625 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address" Indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); Individual XX corporation or other private group entity Individual In	nonprovisional	NO	\$1330	- \$0	\$1330	03/19/2004
1. Change of correspondence address or indication of "Fee Address" (37 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. □ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden	EXAMINER		ART UNIT	CLASS-SUBCLASS	7	
CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Chaving as a member a registered attorney or agents at one pagents and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. Chaving as a member a registered attorney or agents at one pagents at on	ROBINSON, BINTA M		1625	1625 514-415000		
Address form PTO/SB/122) attached. O "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); Individual XX-corporation or other private group entity Individual Indivi	. Change of correspondence CFR 1.363).	e address or indication of "Fe	names of	up to 3 registered patent a	attorneys or 1 MORGAN	, LEWIS &
The Address' Indication (or 'Fee Address' Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); individual Xxcorporation or other private group entity individual in			firm (hav	ing as a member a registered	attorney or 2 BOCKIU	S LLP
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); individual Xxcorporation or other private group entity igovernment da. The following fee(s) are enclosed: 4b. Payment of Fee(s):	PTO/SB/47; Rev 03-02 of	on (or "Fee Address" Indicat or more recent) attached. Use	of a Customer attorneys	or agents. If no name is liste		
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); individual XX corporation or other private group entity government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):	3. ASSIGNEE NAME AND	RESIDENCE DATA TO B	E PRINTED ON THE PATEN	Γ (print or type)		
AstraZeneca AB Sodertalje, Sweden Please check the appropriate assignee category or categories (will not be printed on the patent); 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):						ate when an assignment has ignment.
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):	• •		` '	•		
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):	Please check the appropriate	assignee category or categor	ries (will not be printed on the r	natent): □ individual XX	, comparation or other private or	coun entity. Digovernment
X Issue Fee ☐ A check in the amount of the fee(s) is enclosed.					corporation of other private gr	oup charty G government
	X Issue Fee		☐ A check i	n the amount of the fee(s) is en	closed.	
☐ Publication Fee ☐ Payment by credit card. Form PTO-2038 is attached.						
Advance Order - # of Copies4 May The Director is hereby authorized by charge the required fee(s), or credit any overpayment to Deposit Account Number50-0310 (enclose an extra copy of this form). Any	X Advance Order - # of	Copies4	Mr The Dire Deposit Acc	ctor is hereby authorized by count Number	harge the required fee(s), or (enclose an extra c	credit any overpayment, to opy of this form). Any
Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. deficien	Director for Patents is reque	sted to apply the Issue Fee ar				
(Authorized Signature) (Date)	Authorized Signature)	(all and	(Date)			
Donald J. Bild Reg. No. 25,323 March 18, 2004		_/	7 757 - 7 7 7 7 7			
NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office	NOTE; The Issue Fee and other than the applicant; interest as shown by the re-	Publication Fee (if require a registered attorney or age cords of the United States Pa	d) will not be accepted from	party in		500310 09889599
This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual	This collection of informa obtain or retain a benefit application. Confidentiality	tion is required by 37 CFR by the public which is to fil is governed by 35 U.S.C. 1	1.311. The information is reque (and by the USPTO to proc 22 and 37 CFR 1.14. This colle	iited to l — AB EB-AA	1330.00 DA	
completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.	completed application for case. Any comments on suggestions for reducing t	m to the USPTO. Time will the amount of time you n his burden, should be sent t	vary depending upon the inception of the complete this form the Chief Information Office In	lividual and/or er, U.S.		
case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.	Patent and Trademark (22313-1450. DO NOT S SEND TO: Commissioner	Office, U.S. Department of END FEES OR COMPLE for Patents, Alexandria, Virg	of Commerce, Alexandria, V FED FORMS TO THIS ADD inia 22313-1450.	Virginia DRESS.		:

TRANSMIT THIS FORM WITH FEE(S)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.